Focus: Serena Group is a Cambridge-based biotechnology company specializing in wound care and hyperbaric oxygen therapies, with a focus on rare diseases including diabetic foot ulcers and venous leg ulcers. The company operates a portfolio of medical devices and biologic therapeutics targeting chronic wound management.
Profile data last refreshed 1h ago · AI intelligence enriched 2w ago
Stable — net -1 jobs in 30d
0 added, 1 removed. Backfill posture.
Serena Group offers niche wound-care expertise and clinical trial momentum, but opaque financials and minimal hiring activity suggest cautious evaluation before committing.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Serena Group
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Serena Group's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles